Advanced Drug Delivery Systems:
New Developments, New Technologies
Published September 2003
· The sustained release (oral, injectable and topical) dosage form market is rising at an AAGR of 9.7% is expected to reach $34.1 billion by 2008.
· The transmucosal market is expected to grow at an AAGR of 12.8% and reach $17.7 billion by 2008.
· The market for targeted delivery systems was $7.3 billion in 2002 and will reach $15.5 billion by 2008.
· Transdermal systems and implants and IUDs are expected to climb at AAGRs of 11.1% and 12.4%, respectively.
Source: BCC, Inc.
An application of
biochemical engineering, drug delivery is a formulation or device that delivers
therapeutic agent(s) to desired body location(s) and/or provides timely release
of therapeutic agent(s). It is a system, on its own and is not a therapy, but
improves the efficacy and/or safety of the therapeutic agent(s) that it
carries. Current technology development includes
improvement of safety and efficacy, better compliance and life extension of
products. Drug delivery can offer a number of significant benefits to patients
and physicians, as well as to the pharmaceutical and biotech industries that
employ the specialized services of drug delivery companies. Economics is the
most important driver for the development of drug delivery technology.
The drug delivery market is changing drastically due to the introduction of new techniques and delivery routes. R&D spending along with increasing competition, new technologies, the international marketplace and a changing customer base are contributing creation of systems to a new kind of market in drug delivery systems.
This BCC study looks at the drug delivery system markets affected by these factors. This is a very complex market, with many technologies combined to provide better delivery systems and thus, giving rise to niche markets with very specialized applications. The use of liposomes and polymers in the sustained release oral/injectable drug delivery is a good example.
Inhalation delivery, pegylation, gene therapy and liposomes are emerging and significant new markets. These techniques in combination can be a multibillion-dollar global market, in the next few years. This study discusses the strengths and weaknesses of the drug development market in light of new technologies, growing competition and changing customer needs.
SCOPE OF STUDY
This report provides:
Comprehensive literature and patent searches were conducted. The literature included technical newsletters and journals, as well as many other sources. Data was collected through interviews with personnel from various pharmaceutical and biotech companies. This was complied, and projections were based on such estimates as the current number of end users, potential end users, likely unit prices, consumption rates and market trends.
BCC surveyed many companies to obtain data for this study. Included were manufacturers and end users of drug delivery systems. BCC gathered data from these industries and spoke with their officials, consulted newsletters, company literature, product literature, as well as a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, BCC compiled data from current financial and trade information and government sources.
Shalini Shahani is
a young and enterprising scientist who holds a masters degree in Pharmaceutical
Chemistry. Among the research topics she has covered are: Studies on Compounds
of Potential and Pharmaceutical Interest from Ibuprofen and 2-Naphthyl Acetic
Acid. Shahani was awarded a Gold medal by the prime
RELATED BCC PUBLICATIONS